欢迎来到OAJRC平台！

期刊栏目

投稿

审稿

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据：

当前位置：国际医学与数据杂志 > 2018年 2卷 (1)期

Open Access Article

International Journal of Medicine and Data. 2018; 2: (1) 1; - ; DOI: DOI:10.12208/j.ijmd.20180001.

The structure and functions of follicle-stimulating hormone and its relationship with diseases
卵泡刺激素的结构、功能与疾病关系

作者： 慕云, 詹显全 *

中南大学湘雅医院

中南大学湘雅医院卫生部肿瘤蛋白质组学重点实验室、结构生物学与药物设计、湖南省工程实验室、抗癌药物国家地方联合工程实验室 (长沙，410008)；

*通讯作者：詹显全,单位：中南大学湘雅医院卫生部肿瘤蛋白质组学重点实验室、结构生物学与药物设计、湖南省工程实验室、抗癌药物国家地方联合工程实验室 (长沙，0008)；；

国家高技术“863计划”子项目国家自然科学基金湖南省自然科学基金湖南省百人计划基金湘雅医院人才引进基金

发布时间: 2018-12-24 总浏览量: 5046

PDF 全文下载引用本文收录截图（CNKI-Scholar）

摘要

卵泡刺激素是垂体糖蛋白激素家族中的一种，它对于维持正常的生殖功能具有十分重要意义，尤其是对阐明生殖生理过程、诊断和治疗生殖系统疾病非常重要。卵泡刺激素的生物学活性是一系列复杂进程的综合：从垂体中合成释放，存在于血液循环中，随血液循环转运至靶器官，与靶点受体结合，调节生长发育，卵泡成熟和精子发生等。本文综述了近年来在卵泡刺激素结构、功能及其与疾病关系的研究进展。

关键词： 卵泡刺激素、结构与功能、临床治疗应用

Abstract

Follicle-stimulating hormone (FSH) is a member of glycoprotein hormone superfamily. It is crucial in maintaining normal fertilization, especially in elucidating fertilization process, diagnosing and curing reproductive system diseases. The activation of FSH is a series of comprehensive process. It is synthesized and secreted by the gonadotroph cells in the anterior pituitary gland and transported through blood to the target organ and binds to the target receptors to regulate development, growth, follicular maturation, and spermatogenesis. This article reviews the research progress in the structure, function, and related diseases of FSH these years.

Key words： Follicle-stimulating hormone, structure and function, clinical therapeutic application

参考文献 References

[1] Jiang X, Fischer D, Chen X, et al. Evidence for follicle-stimulating hormone receptor as a functional trimer.J Biol Chem,2014 289 (20) : 14273-14282.

[2] Dias, J.A. Molecular,structural,and cellular biology of follitropin and follitropin receptor .Vitam Horm ,2002 64 : 249 -322 .

[3] Mayorga M, Gromoll J, Behre H, et al. Ovarian response to follicle-stimulating hormone(FSH) stimulation depends on the FSH receptor genotype.J Clin Endocrinol Metab,2000 85 (9) : 3365-3369.

[4] Themmen APN, Huhtaniemi, IT. Mutations of gonadotropins and gonadotropin receptors:elucidating the physiology and pathophysiology of pituitary-gonadal function .Endocr Rev ,2000 21 : 551-583.

[5] Ryan RJ, Charlesworth MC, McCormick DJ, et al. The glycoprotein hormones:recent studies of structure-function relationships.FASEB J,1988 2 (11) : 2661-2669.

[6] Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors:Elucidating the physiology and pathophysiology of pituitary-gonadal function.Endocr Rev,2000 21 : 551-583.

[7] Szkudlinski M. New frontier in glycoprotein hormones and their receptors structure-function.Front Endocrinol,2015 6 : 155.

[8] Nunez M, Sanders J, Fumaniak J, et al. Glycosylation pattern analysis of glycoprotein hormones and their receptors.J Mol Endocrinol,2017 58 (1) : 25-41.

[9] Rose M, Gaines D, Balen A, et al. Definition and measurement of follicle stimulating hormone.Endocr Rev,2000 21 (1) : 5-22.

[10] Kristin M.Fox, James A.Dias, and Patrick Van Roey. Three-Dimensional Structure of Human Follicle-Stimulating Hormone .Mol Endocrinol ,2000 15 (3 ) : 378-389.

[11] Alevizaki M, Huhtaniemi L. Structure-function relationships of glycoprotein hormones; lessons from mutations and polymorphisms of the thyrotrophin and gonadotrophin subunit genes.Hormones,2002 1 (4) : 224-232.

[12] Amla Kuechler, Berthold P Hauffa, Angela Ko ninger. An unbalanced translocation unmasks a recessive mutation in the follicle-stimulating hormone receptor(FSHR) gene and causes FSH resistance .Eur J Human Genet ,2010 18 : 656-661.

[13] Ulloa-Aguirre A, Zarinan T. The follitropin receptor: matching structure and function.Mol Pharmacol,2016 90 (5) : 596-608.

[14] Papadimitriou K, Kountourakis P, Kottorou AE. Follicle-stimulating hormone receptor(FSHR): a promising tool in oncology?.Mol Diagn Ther ,2016 20 (6 ) : 523 -530 .

[15] Meher BR, Dixit A, Bousfield GR, et al. Glycosylation effects on FSH-FSHR interaction Dynamics:A Case Study of Different FSH Glycoforms by Molecular Dynamics Simulations .Plos One ,2015 10 (9 ) : - .

[16] Fan QR, Hendrickson WA. Structure of human follicle-stimulating hormone in complex with its receptor.Nature,2005 433 (7023) : 269-277.

[17] Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: Elucidating the physiology and pathophysiology of pituitary-gonadal function.Endocr Rev,2000 21 : 551-583.

[18] Huhtaniemi I, Alevizaki M. Gonadotrophin resistance.Best Pract Res Clin Endocinol Metab,2006 20 : 561-576.

[19] Ulloa-Aguirre A, Timossi C, Barrios-de-Tomasi J,et al. Impact of carbohydrate heterogeneity in function of follicle-stimulating hormone:Studies derived from in vitro and in vivo models .Biol Reprod ,2003 69 : 379-389.

[20] Gromoll J, Simoni M. Genetic complexity of FSH receptor function.Trends Endocrinol Metab,2005 16 : 368-373.

[21] Sanchez-Cardenas, C. & Hernandez-Cruz, A. GnRH-Induced [Ca2+]isignalling patterns in mouse gonadotrophs recorded from acute pituitary slices in vitro .Neuroendocrinol ,2010 91 : 239 -255 .

[22] Lindsey K. Roper, Joseph S. Briguglio, Chantell S. Evans. Sex-specific regulation of follicle-stimulating hormone secretion by synaptotagmin 9 .Nat Commun ,2015 6 : 8645 - .

[23] Liu X, Chan H, Ding G, et al. FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca2+/CREB pathway.Aging Cell,2015 14 : 409-420.

[24] Visser JA, Schipper I, Laven JS. Anti-müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.Nat Rev Endocrinol,2012 8 (6) : 331-341.

[25] Mizunuma H, Takagi T, Honjyo S, Ibuki Y, Igarashi M. Clinical pharmacodynamics of urinary follicle-stimulating hormone and its application for pharmacokinetic simulation program.Fertil Steril,1990 53 (3) : 440-445.

[26] Qiu Q, Kuo A, Todd H, Dias JA, Gould JE, Overstreet JW, Lasley BL. Enzyme immunoassay method for total urinary follicle-stimulating hormone (FSH) beta subunit and its application for measurement of total urinary FSH.Fertil Steril,1998 69 (2) : 278-285.

[27] Howles CM. Role of LH and FSH in ovarian function.Mol Cell Endocrinol,2000 161 (1-2) : 25-30.

[28] Ganesh V, Venkatesan V, Koshy T, Reddy SN, Muthumuthiah S, Paul SFD. Association of estrogen, progesterone and follicle stimulating hormone receptor polymorphisms with in vitro fertilization outcomes.Syst Biol Reprod Med,2018 64 (4) : 260-265.

[29] Colacurci N, De Leo V, Ruvolo G, Piomboni P, Caprio F, Pivonello R, Papaleo E, La Verde E, Depalo R, Lispi M, Longobardi S, Paoli D, Pallotti F, Lombardo F. Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial.Front Endocrinol (Lausanne),2018 9 : 383.

[30] Chan Y, Zhu B, Zhang J, Luo Y, Tang W. Associations Between TP53 and MDM2 Polymorphisms and the Follicle-Stimulating Hormone/Luteinizing Hormone Ratio in Infertile Women.Genet Test Mol Biomarkers,2018 22 (7) : 405-412.

[31] Alizadeh M, Nasebakht A, Valizadeh R, Mohammadi Fallah M, Taghizadeh Afshari A, Rahimi MM, Daneshyar C. A preliminary evaluation of serum level of testosterone, LH, and FSH in patients with varicocele after varicocelectomy as a kidney-related disease.Ther Clin Risk Manag,2018 14 : 1585-1590.

[32] Chu MC, Rath KM, Huie J, Taylor HS. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk.Hum Reprod,2003 18 (8) : 1570-1573.

[33] Miyazaki K, Miki F, Uchida S, Masuda H, Uchida H, Maruyama T. Serum estradiol level during withdrawal bleeding as a predictive factor for intermittent ovarian function in women with primary ovarian insufficiency.Endocr J,2015 62 (1) : 93-99.

[34] Hwang JL, Chen SU, Chen HJ, Chen HF, Yang YS, Chang CH, Seow KM, Tzeng CR, Lin YH. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.J Formos Med Assoc,2018 117 (6) : 535-540.

[35] Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.J Assist Reprod Genet,2018 35 (2) : 297-307.

[36] Bishop LA, Richter KS, Patounakis G, Andriani L, Moon K, Devine K. Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients.Fertil Steril,2017 108 (6) : 980-987.

[37] Chihaoui M, Kanoun F, Chaker F, Yazidi M, Bouchrit K, Mizouni H, Feki M, Kharrat M, Slimane H. Testicular adrenal rest tumours in young adult males with congenital adrenal hyperplasia: prevalence and impact on testicular function.Andrologia,2016 48 (1) : 45-50.

[38] Hart RJ, Doherty DA, McLachlan RI, Walls ML, Keelan JA, Dickinson JE, Skakkebaek NE, Norman RJ, Handelsman DJ. Testicular function in a birth cohort of young men.Hum Reprod,2015 30 (12) : 2713-2724.

[39] Zheng J, Mao J, Cui M, et al. Novel FSHβ mutation in a male patient with isolated FSH deficiency and infertility.Eur J Med Genet,2017 60 (6) : 335-339.

[40] Wang H, Chen X, Zhang X, Zhang W, Li Y, Yin H, Shao H, Chen G. Comparative Assessment of Glycosylation of a Recombinant Human FSH and a Highly Purified FSH Extracted from Human Urine.J Proteome Res,2016 15 (3) : 923-932.

[41] Zhang M, Tong G, Liu Y, Mu Y, Weng J, Xue Y, Luo Z, Xue Y, Shi L, Wu X, Sun S, Zhu Y, Cao Y, Zhang J, Huang H, Niu B, Li H, Guo Q, Gao Y, Li Z, Ning G, Zhu D, Li X; HHIS Study Group. Sequential Versus Continual Purified Urinary FSH/hCG in Men With Idiopathic Hypogonadotropic Hypogonadism.J Clin Endocrinol Metab,2015 100 (6) : 2449-2455.

[42] Barriere P, Porcu-Buisson G, Hamamah S. Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis.Appl Health Econ Health Policy,2018 16 (1) : 65-77.

[43] Barrenetxea G, García-Velasco JA, Aragón B, Osset J, Brosa M, López-Martínez N, Coroleu B. Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study.Reprod Biomed Soc Online,2018 5 : 46-59.

[44] Mendret-Pellerin S, Leperlier F, Reignier A, Lefebvre T, Barrière P, Fréour T. A pilot study comparing corifollitropin alfa associated with hp-HMG versus high dose rFSH antagonist protocols for ovarian stimulation in poor responders.Hum Fertil (Camb),2018 8 (21) : 1-8.

[45] Abd-Elaziz K, Duijkers I, Stöckl L, Dietrich B, Klipping C, Eckert K, Goletz S. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.Hum Reprod,2017 32 (8) : 1639-1647.

[46] OO General. Bone Health and Osteoporosis: A Report of the Surgeon General.Office of the Surgeon General,2004 4 (3) : 379-382.

[47] Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass .Cell ,2006 125 : 247-260.

[48] Imai Y. Bone metabolism by sex hormones and gonadotropins .Clin Calcium ,2014 24 (6 ) : 815-819.

[49] Sowers MR, Zheng H, Greendale GA, et al. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity .J Clin Endocrinol Metab ,2013 98 : 2854-2863.

[50] Sowers MR, Jannausch M, McConnell D, et al. Hormone predictors of bone mineral density changes during the menopausal transition .J Clin Endocrinol Metab ,2006 91 : 1261-1267.

[51] Xu ZR, Wang AH, Wu XP, et al. Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women .Clin Chim Acta ,2009 400 : 8-13.

[52] Zhu LL, Tourkova I, Yuen T, et al. Blocking FSH action attenuates osteoclastogenesis .Biochem Biophys Res Commun ,2012 422 : 54-58.

[53] Zaidi M, Blair HC, Iqbal J, et al. New insights: elevated follicle-stimulating hormone and bone loss during the menopausal transition. Curr Rheumatol Rep,2009 11 : 191-195.

[54] Siraj A, Desestret V, Antoine M, et al. Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases.BMC Cancer,2013 13 : 246.

[55] Ide H, Terado Y, Sakamaki K, et al. Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer.Prostate Int,2013 1 (3) : 109-112.

[56] Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels.N Engl J Med,2010 363 : 1621-1630.

[57] Planeix F, Siraj MA, Bidard FC, et al. Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery.J Exp Clin Cancer Res,2015 34 : 12.

[58] Pawlikowski M, Radek M, Jaranowska M, et al. Expression of follicle stimulating hormone receptors in pituitary adenomas - a marker of tumor aggressiveness? .Endokrynol Pol ,2014 65 (6 ) : 469 -471 .

引用本文

慕云, 詹显全, 卵泡刺激素的结构、功能与疾病关系[J]. 国际医学与数据杂志, 2018; 2: (1) : -.

入驻平台

回到首页

搜索文章: